Table 5 Association of ERCC2 and MTHFR haplotypes with clinical characteristics of breast cancer patients

Haplotype

(n = 302)

OR (95% CI)^a

p ^b

> 40

≤40

 C-A

49.8% ^c

49.4%

1

–

 T-A

23.9%

26.5%

1.08 (0.61–1.93)

0.78

 C-C

21.2%

8.7%

0.44 (0.16–1.16)

0.1

 T-C

5.1%

15.4%

3.52 (1.23–10.06)

0.02

 G-A

51.3%

48.1%

1

–

 A-A

18.7%

20.7%

1.23 (0.65–2.35)

0.53

 G-C

15.5%

18.9%

1.33 (0.68–2.61)

0.41

 A-C

14.5%

12.3%

0.91 (0.47–1.76)

0.79

Haplotype

(n = 302)

Sporadic

Familial

 C-A

53.5%

46.6%

1

–

 T-A

17.9%

31.1%

1.76 (0.97–3.18)

0.063

 C-C

24.5%

7.4%

0.36 (0.14–0.95)

0.042

 T-C

4.1%

14.9%

4.96 (1.50–16.42)

0.0097

 G-A

51.1%

48.7%

1

–

 A-A

19.1%

20.2%

1.05 (0.56–1.98)

0.88

 G-C

18.4%

15.5%

0.87 (0.44–1.68)

0.67

 A-C

11.4%

15.6%

1.32 (0.70–2.47)

0.39

Haplotype

(n = 286)

ER positive

ER negative

 G-A

46.7%

57.6%

1

–

 A-A

19.6%

17.4%

0.83 (0.38–1.81)

0.65

 G-C

15.9%

20.2%

1.11 (0.54–2.30)

0.78

 A-C

17.8%

4.8%

0.28 (0.09–0.88)

0.03

rs1799793-rs13181

PR positive

PR negative

 G-A

48.7%

48.3%

1

–

 A-A

19.3%

20.5%

1.41 (0.67–2.98)

0.36

 G-C

13.1%

25.7%

2.34 (1.1–4.96)

0.02

 A-C

18.9%

5.6%

0.33 (0.12–0.92)

0.03

Haplotype

(n = 72)

T1

T4

 G-A

55.5%

41.7%

1

–

 A-A

17.4%

29.2%

2.10 (0.59–7.46)

0.26

 G-C

11.2%

29.1%

23.30 (2.03–267.69)

0.017

 A-C

15.9%

0%

NA

1